Timothée Olivier, MD
@Timothee_MD
Followers
2K
Following
3K
Media
401
Statuses
2K
Oncology (sarcoma, H&N, CUP). EBM, Health Policy @HUG_ge (Geneva), @vkprasadlab (UCSF). Geneva Ethics Committee. Co-EiC ESMO Rare Cancers. No COI. Views mine.
Genève, Suisse
Joined December 2021
RT @oncodaily: @Alfdoc2 @hug_ge @Timothee_MD We would like to inform you that your post has been published on OncoDaily. Thank you for shar….
0
1
0
RT @Alfdoc2: Today’s Tuesday scientific colloquium at @hug_ge featured a timely and thought-provoking presentation by @Timothee_MD, on the….
0
2
0
Updated online applications:.22 @US_FDA approvals in the neoadjuvant and/or adjuvant settings between 2018 and 2025. Number needed to treat? survival benefit? how to interpret survival in the context of post-recurrence care? and more!. - registration trials with key data here
3
8
21
RT @NIHDirector_Jay: This 4th of July, I’m reflecting on the freedoms that fuel scientific rigor and public health. From all of us at @NIH,….
0
300
0
RT @US_FDA: Today, FDA provided important updates on the risk of myocarditis after receiving an mRNA COVID-19 vaccine, noting the risk is h….
0
2K
0
RT @anish_koka: The times article claims @VPrasadMDMPH overruled FDA staff by not recommending the current novavax covid vaccine to healthy….
0
9
0
The CONTACT-02 trial is now published! We already performed (and published in EJC) a sensitivity analysis based on digitized curves from the ASCO-GU presentation in Jan 2024. Thanks to @TheLancetOncol, we have now the number of patients censored at each time interval. -> This
🆕in July issue: Cabozantinib plus atezolizumab in metastatic #prostatecancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial. @montypal, @neerajaiims, and colleagues
3
7
17
Very nice video!. Congratulations to @VPrasadMDMPH for his nomination as the @US_FDA’s Chief Medical and Scientific Officer, in addition to his position as the @FDACBER Director, this is huge news ! . Great decision @DrMakaryFDA 👍.
In our latest FDA Direct conversation learn how we're enhancing drug development and accelerating cures for all Americans through the Commissioner’s National Priority Voucher program.
2
3
21
RT @myESMO: Two studies investigating efficacy of bispecific T-cell engager tarlatamab and lurbinectedin–atezolizumab combination met their….
0
12
0
RT @oncodaily: @Timothee_MD We would like to inform you that your post has been published on Thank you for sharing….
0
1
0
This tweet, like many others you've posted in recent days about Vinay, and about the new FDA that could be worse than the old one etc., are, in my view, in very poor taste, for several reasons. 1- "VP", as you call him, has shaped many of your ideas over the years.2- Vinay has.
What happened to VP? What is the incredible promise of RWD?.
23
2
26
RT @Timothee_MD: @MrPug94 @PTarantinoMD Criticizing for criticizing?? No way. I’m matter of fact: we need replication.
0
3
0
RT @NickMullenMDPhD: Congratulations to @VPrasadMDMPH! This is a huge win for evidence-based medicine and common sense.
0
1
0
One of my #ASCO25 highlights was connecting "in person" with great people I used to interact with, whom I admire a lot. It was one of my best #ASCO25 moments to finally meet the great @rajshekharucms and have fascinating and friendly discussions ! (and 👍🇳🇵food !)
3
0
17
RT @ClarkHenegan: @AaronGoodman33 @NiuSanford Telling your patient to exercise and giving them information on it was the control arm in CHA….
0
4
0